Arbutus files patent infringement suits against Pfizer, BioNTech over LNP technology
I'm LongbridgeAI, I can summarize articles.Arbutus Biopharma filed patent infringement lawsuits against Pfizer and BioNTech in Canada and Europe regarding lipid nanoparticle (LNP) technology. The suits seek damages and injunctions for products infringing specific patents, including mRNA-LNP COVID-19 vaccines. Additionally, Arbutus received USD 178 million from a Moderna settlement and plans share repurchases starting Q3 2026.
- Arbutus Biopharma filed patent infringement suits against Pfizer, BioNTech in Canada, Europe tied to its lipid nanoparticle technology. * Actions seek damages, injunctions covering Pfizer-BioNTech mRNA-LNP COVID-19 vaccines, other products alleged to infringe Canadian Patent 2,721,333. * European cases target EP 4 241 767, EP 4 495 237 in the Unified Patent Court, seeking injunctions, monetary relief across multiple member states. * Received USD 178 million from Moderna under a March 2026 settlement over LNP patent litigation, including litigation cost reimbursement. * Plans to return up to about USD 230 million via share repurchases starting in Q3 2026, contingent on an expected Genevant-related dividend. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arbutus Biopharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160730PRIMZONEFULLFEED9763343) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)